Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

NCT07243951 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Combined Hepatocellular-cholangiocarcinoma
Liver Neoplasms

Interventions

DRUG: Cadonilimab
DRUG: Capecitabine

Sponsor

Shanghai Zhongshan Hospital